Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 17, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific director transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a transaction involving Dr. L. Shapiro, a Director. On February 15, 2006, 296 American Depository Shares (ADS) were purchased for Dr. Shapiro at a price of $51.04 per share. This purchase was executed under the share election arrangements for the GlaxoSmithKline Scientific Advisory Board Share Allocation Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The transaction was notified in accordance with Disclosure rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of ADS held by Dr. L. Shapiro following this transaction.
- Confirm the terms of the GlaxoSmithKline Scientific Advisory Board Share Allocation Plan.
- Check for any other director transactions reported in subsequent filings for the same period.